title: Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.
abstract: BACKGROUND
  Initiation of combination antiretroviral therapy (ART) results in higher total CD4 cell counts, a surrogate for immune reconstitution. Whether the baseline CD4 cell count affects reconstitution of immune cell subsets has not been well characterized.
  
  
  METHODS
  Using data from 978 patients (621 with comprehensive immunological assessments) from the AIDS [Acquired Immunodeficiency Syndrome] Clinical Trials Group protocol 384, a randomized trial of initial ART, we compared reconstitution of CD4(+), CD4(+) naive and memory, CD4(+) activation, CD8(+), CD8(+) activation, B, and natural killer cells among patients in different baseline CD4(+) strata. Reference ranges for T cell populations in control patients negative for human immunodeficiency virus (HIV) infection were calculated using data from AIDS Clinical Trials Group protocol A5113.
  
  
  RESULTS
  Patients in the lower baseline CD4(+) strata did not achieve total CD4(+) cell counts similar to those of patients in the higher strata during 144 weeks of ART, although CD4(+) cell count increases were similar. Ratios of CD4(+) naive-memory cell counts and CD4(+):CD8(+) cell counts remained significantly reduced in patients with lower baseline CD4(+) cell counts (<or=350 cells/mm(3)). These immune imbalances were most notable for those initiating ART with a baseline CD4(+) cell count <or=200 cells/mm(3), even after adjustment for baseline plasma HIV RNA levels.
  
  
  CONCLUSIONS
  After nearly 3 years of ART, T cell subsets in patients with baseline CD4(+) cell counts >350 cells/mm(3) achieved or approached the reference range those of control individuals without HIV infection. In contrast, patients who began ART with <or=350 CD4(+) cells/mm(3) generally did not regain normal CD4(+) naive-memory cell ratios. These results support current guidelines to start ART at a threshold of 350 cells/mm(3) and suggest that there may be immunological benefits associated with initiating therapy at even higher CD4(+) cell counts.
authors.affiliation: Infectious Diseases Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. grobbins@partners.org
authors.forename: Gregory K
authors.initials: GK
authors.lastname: Robbins
authors.forename: John G
authors.initials: JG
authors.lastname: Spritzler
authors.forename: Ellen S
authors.initials: ES
authors.lastname: Chan
authors.forename: David M
authors.initials: DM
authors.lastname: Asmuth
authors.forename: Rajesh T
authors.initials: RT
authors.lastname: Gandhi
authors.forename: Benigno A
authors.initials: BA
authors.lastname: Rodriguez
authors.forename: Gail
authors.initials: G
authors.lastname: Skowron
authors.forename: Paul R
authors.initials: PR
authors.lastname: Skolnik
authors.forename: Robert W
authors.initials: RW
authors.lastname: Shafer
authors.forename: Richard B
authors.initials: RB
authors.lastname: Pollard
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001402:B-Lymphocytes / Q000276:immunology; D018791:CD4 Lymphocyte Count; D016516:CD4-CD8 Ratio; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000276:immunology*